Antipsychotic medication during the critical period following remission from first-episode psychosis: Less is more

JAMA Psychiatry

Volumn 70, Issue 9, 2013, Pages 898-900

  McGorry, Patrick ^a   Alvarez Jimenez, Mario ^a   Killackey, Eoin ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; NEUROLEPTIC AGENT;

BEHAVIOR DISORDER; CLINICAL PRACTICE; CONVALESCENCE; DISTRESS SYNDROME; EDITORIAL; HUMAN; LOW DRUG DOSE; PSYCHOSIS; PSYCHOSOCIAL CARE; RECURRENT DISEASE; REMISSION;

EID: 84883536985     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.264     Document Type: Editorial

References (14)

1. Alvarez-Jimenez M, Priede A, Hetrick SE, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139(1-3):116-128.
2. Chen EY, Hui CL, Lam MM, et al. Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ. 2010;341:c4024. doi:10.1136/bmj.c4024.
3. Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr Res. 2012;138(1):29-34.
4. Gitlin M, Nuechterlein K, Subotnik KL, et al. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001;158(11):1835-1842. (Pubitemid 33054776)
5. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial [published online July 3, 2013]. JAMA Psychiatry. doi:10.1001/jamapsychiatry.2013.19.
6. Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007;68(5):654-661. (Pubitemid 46841847)
7. Bitter I, Volavka J, Scheurer J. The concept of the neuroleptic threshold: an update. J Clin Psychopharmacol. 1991;11(1):28-33.
8. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991;48(8):739-745.
9. Kapur S. A new framework for investigating antipsychotic action in humans: lessons from PET imaging. Mol Psychiatry. 1998;3(2):135-140. (Pubitemid 28149554)
10. Álvarez-Jiménez M, Gleeson JF, Henry LP, et al. Road to full recovery: longitudinal relationship between symptomatic remission and psychosocial recovery in first-episode psychosis over 7.5 years. Psychol Med. 2012;42(3):595-606.
11. Killackey E, Jackson HJ, McGorry PD. Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. Br J Psychiatry. 2008;193(2):114-120.
12. Gleeson JF, Cotton SM, Alvarez-Jimenez M, et al. A randomized controlled trial of relapse prevention therapy for first-episode psychosis patients: outcome at 30-month follow-up. Schizophr Bull. 2013;39(2):436-448.
13. Alvarez-Jimenez M, Bendall S, Lederman R, et al. On the HORYZON: moderated online social therapy for long-term recovery in first episode psychosis. Schizophr Res. 2013;143(1):143-149.
14. Francey SM, Nelson B, Thompson A, et al. Who needs antipsychotic medication in the earliest stages of psychosis? a reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. Schizophr Res. 2010;119(1-3):1-10.